{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,9]],"date-time":"2026-11-09T20:06:50Z","timestamp":1794254810569,"version":"4.9.0"},"reference-count":89,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","license":[{"start":{"date-parts":[[2025,4,11]],"date-time":"2025-04-11T00:00:00Z","timestamp":1744329600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-sa\/4.0"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,7]]},"abstract":"<jats:title>\n                    A\n                    <jats:sc>BSTRACT<\/jats:sc>\n                  <\/jats:title>\n                  <jats:p>Uremic toxins (UTs) are bioactive compounds that accumulate in chronic kidney disease (CKD) due to impaired renal clearance, exacerbating disease progression and cardiovascular (CV) complications. These toxins originate from endogenous metabolism, gut microbiota, and dietary intake and include protein-bound UTs such as p-cresyl sulfate, indoxyl sulfate, and indole acetic acid, as well as small, water-soluble toxins such as trimethylamine-N-oxide and phenylacetylglutamine. Their accumulation promotes oxidative stress, inflammation, and endothelial dysfunction, contributing to vascular damage and associated with CV risk. Current management strategies focus on dietary interventions, prebiotics, probiotics, oral sorbents, emerging pharmacological approaches, and advanced dialysis techniques, but clinical outcomes remain inconsistent. Recent trials have demonstrated the potential of agents such as sevelamer, high-amylose-resistant starch, and AST-120 to reduce UT levels and improve certain vascular markers. However, more robust, long-term studies are necessary to fully establish the therapeutic efficacy and optimize treatment strategies to mitigate the impact of gut-derived UTs on CKD and CV health.<\/jats:p>","DOI":"10.4103\/tcmj.tcmj_293_24","type":"journal-article","created":{"date-parts":[[2025,4,11]],"date-time":"2025-04-11T06:00:13Z","timestamp":1744351213000},"page":"264-274","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":25,"title":["Gut-derived uremic toxins and cardiovascular health in chronic kidney disease"],"prefix":"10.4103","volume":"37","author":[{"given":"Ming-Chun","family":"Chen","sequence":"first","affiliation":[{"name":"Department of Pediatrics, Hualien Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Hualien, Taiwan"},{"name":"School of Medicine, Tzu Chi University, Hualien, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiu-Huang","family":"Kuo","sequence":"additional","affiliation":[{"name":"School of Post-Baccalaureate Chinese Medicine, Tzu Chi University, Hualien, Taiwan"},{"name":"Division of Nephrology, Hualien Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Hualien, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Li","family":"Lin","sequence":"additional","affiliation":[{"name":"School of Medicine, Tzu Chi University, Hualien, Taiwan"},{"name":"Division of Nephrology, Hualien Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Hualien, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bang-Gee","family":"Hsu","sequence":"additional","affiliation":[{"name":"School of Medicine, Tzu Chi University, Hualien, Taiwan"},{"name":"Division of Nephrology, Hualien Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Hualien, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,4,11]]},"reference":[{"key":"R1-20250701","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1111\/j.1525-139X.2005.18313.x","article-title":"Uremic toxins:A new focus on an old subject","volume":"18","author":"Yavuz","year":"2005","journal-title":"Semin Dial"},{"key":"R2-20250701","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1159\/000528040","article-title":"Proposal for a new classification of solutes of interest in uremia and hemodialysis","volume":"52","author":"Kashani","year":"2023","journal-title":"Blood Purif"},{"key":"R3-20250701","doi-asserted-by":"crossref","first-page":"1918","DOI":"10.2215\/CJN.02660221","article-title":"Classification of uremic toxins and their role in kidney failure","volume":"16","author":"Rosner","year":"2021","journal-title":"Clin J Am Soc Nephrol"},{"key":"R4-20250701","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1093\/ckj\/sfv004","article-title":"The intestine and the kidneys:A bad marriage can be hazardous","volume":"8","author":"Vanholder","year":"2015","journal-title":"Clin Kidney J"},{"key":"R5-20250701","doi-asserted-by":"crossref","first-page":"590","DOI":"10.3390\/toxins12090590","article-title":"Gut-derived protein-bound uremic toxins","volume":"12","author":"Graboski","year":"2020","journal-title":"Toxins (Basel)"},{"key":"R6-20250701","doi-asserted-by":"crossref","first-page":"245","DOI":"10.3390\/toxins12040245","article-title":"Gut-derived metabolites and their role in immune dysfunction in chronic kidney disease","volume":"12","author":"Glorieux","year":"2020","journal-title":"Toxins (Basel)"},{"key":"R7-20250701","doi-asserted-by":"crossref","first-page":"10397","DOI":"10.3390\/ijms251910397","article-title":"Low-molecular-weight compounds produced by the intestinal microbiota and cardiovascular disease","volume":"25","author":"Cuervo","year":"2024","journal-title":"Int J Mol Sci"},{"key":"R8-20250701","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1681\/ASN.2013080905","article-title":"The gut microbiome, kidney disease, and targeted interventions","volume":"25","author":"Ramezani","year":"2014","journal-title":"J Am Soc Nephrol"},{"key":"R9-20250701","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1042\/CS20171107","article-title":"Altered microbiome in chronic kidney disease:Systemic effects of gut-derived uremic toxins","volume":"132","author":"Lau","year":"2018","journal-title":"Clin Sci (Lond)"},{"key":"R10-20250701","doi-asserted-by":"crossref","first-page":"91","DOI":"10.3390\/toxins13020091","article-title":"Intestinal chelators, sorbants, and gut-derived uremic toxins","volume":"13","author":"Laville","year":"2021","journal-title":"Toxins (Basel)"},{"key":"R11-20250701","doi-asserted-by":"crossref","first-page":"3994","DOI":"10.1080\/10408398.2021.1996331","article-title":"Dietary strategies for gut-derived protein-bound uremic toxins and cardio-metabolic risk factors in chronic kidney disease:A focus on dietary fibers","volume":"63","author":"Melekoglu","year":"2023","journal-title":"Crit Rev Food Sci Nutr"},{"key":"R12-20250701","doi-asserted-by":"crossref","first-page":"151408","DOI":"10.1016\/j.semnephrol.2023.151408","article-title":"Gut microbiota-targeted interventions in the management of chronic kidney disease","volume":"43","author":"Sumida","year":"2023","journal-title":"Semin Nephrol"},{"key":"R13-20250701","doi-asserted-by":"crossref","first-page":"2214","DOI":"10.1093\/ckj\/sfac154","article-title":"Decreasing microbiota-derived uremic toxins to improve CKD outcomes","volume":"15","author":"Beker","year":"2022","journal-title":"Clin Kidney J"},{"key":"R14-20250701","doi-asserted-by":"crossref","first-page":"52","DOI":"10.3390\/toxins9020052","article-title":"p-cresyl sulfate","volume":"9","author":"Gryp","year":"2017","journal-title":"Toxins (Basel)"},{"key":"R15-20250701","doi-asserted-by":"crossref","first-page":"358","DOI":"10.3390\/toxins8120358","article-title":"Indoxyl sulfate-review of toxicity and therapeutic strategies","volume":"8","author":"Leong","year":"2016","journal-title":"Toxins (Basel)"},{"key":"R16-20250701","doi-asserted-by":"crossref","first-page":"412","DOI":"10.3390\/toxins10100412","article-title":"Tryptophan-derived uremic toxins and thrombosis in chronic kidney disease","volume":"10","author":"Addi","year":"2018","journal-title":"Toxins (Basel)"},{"key":"R17-20250701","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1053\/j.jrn.2015.06.004","article-title":"Trimethylamine n-oxide from gut microbiota in chronic kidney disease patients:Focus on diet","volume":"25","author":"Moraes","year":"2015","journal-title":"J Ren Nutr"},{"key":"R18-20250701","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.chom.2022.11.015","article-title":"Two distinct gut microbial pathways contribute to meta-organismal production of phenylacetylglutamine with links to cardiovascular disease","volume":"31","author":"Zhu","year":"2023","journal-title":"Cell Host Microbe"},{"key":"R19-20250701","doi-asserted-by":"crossref","first-page":"142","DOI":"10.3390\/toxins13020142","article-title":"Uremic toxins in the progression of chronic kidney disease and cardiovascular disease:Mechanisms and Therapeutic Targets","volume":"13","author":"Lim","year":"2021","journal-title":"Toxins (Basel)"},{"key":"R20-20250701","doi-asserted-by":"crossref","first-page":"280","DOI":"10.3390\/toxins14040280","article-title":"Uremic toxins and cardiovascular risk in chronic kidney disease:What have we learned recently beyond the past findings?","volume":"14","author":"El Chamieh","year":"2022","journal-title":"Toxins (Basel)"},{"key":"R21-20250701","doi-asserted-by":"crossref","first-page":"e001852","DOI":"10.1161\/JAHA.115.001852","article-title":"p-cresyl sulfate aggravates cardiac dysfunction associated with chronic kidney disease by enhancing apoptosis of cardiomyocytes","volume":"4","author":"Han","year":"2015","journal-title":"J Am Heart Assoc"},{"key":"R22-20250701","doi-asserted-by":"crossref","first-page":"e00092","DOI":"10.1002\/prp2.92","article-title":"p-cresyl sulfate, a uremic toxin, causes vascular endothelial and smooth muscle cell damages by inducing oxidative stress","volume":"3","author":"Watanabe","year":"2015","journal-title":"Pharmacol Res Perspect"},{"key":"R23-20250701","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1681\/ASN.2018060609","article-title":"Indoxyl sulfate and p-cresyl sulfate promote vascular calcification and associate with glucose intolerance","volume":"30","author":"Opdebeeck","year":"2019","journal-title":"J Am Soc Nephrol"},{"key":"R24-20250701","doi-asserted-by":"crossref","first-page":"e0132589","DOI":"10.1371\/journal.pone.0132589","article-title":"Meta-analysis of the associations of p-cresyl sulfate (PCS) and indoxyl sulfate (IS) with cardiovascular events and all-cause mortality in patients with chronic renal failure","volume":"10","author":"Lin","year":"2015","journal-title":"PLoS One"},{"key":"R25-20250701","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1093\/ndt\/gfab004","article-title":"Free p-cresyl sulfate shows the highest association with cardiovascular outcome in chronic kidney disease","volume":"36","author":"Glorieux","year":"2021","journal-title":"Nephrol Dial Transplant"},{"key":"R26-20250701","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1080\/0886022X.2022.2136528","article-title":"p-cresyl sulfate predicts clinical outcomes in sustained peritoneal dialysis:A 5-year follow-up cohort study and meta-analysis","volume":"44","author":"Chen","year":"2022","journal-title":"Ren Fail"},{"key":"R27-20250701","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.1016\/j.kint.2017.05.012","article-title":"Results of the HEMO study suggest that p-cresol sulfate and indoxyl sulfate are not associated with cardiovascular outcomes","volume":"92","author":"Shafi","year":"2017","journal-title":"Kidney Int"},{"key":"R28-20250701","doi-asserted-by":"crossref","first-page":"229","DOI":"10.3390\/toxins12040229","article-title":"Indoxyl sulfate, a uremic endotheliotoxin","volume":"12","author":"Lano","year":"2020","journal-title":"Toxins (Basel)"},{"key":"R29-20250701","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1093\/ckj\/sfaa121","article-title":"Serum total indoxyl sulfate and clinical outcomes in hemodialysis patients:Results from the Japan dialysis outcomes and practice patterns study","volume":"14","author":"Yamamoto","year":"2021","journal-title":"Clin Kidney J"},{"key":"R30-20250701","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1159\/000521422","article-title":"Association between cardiac outcomes and indoxyl sulfate levels in hemodialysis patients:A cross-sectional study","volume":"47","author":"Li","year":"2022","journal-title":"Kidney Blood Press Res"},{"key":"R31-20250701","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1681\/ASN.2013121283","article-title":"The cardiovascular effect of the uremic solute indole-3 acetic acid","volume":"26","author":"Dou","year":"2015","journal-title":"J Am Soc Nephrol"},{"key":"R32-20250701","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.3390\/ijms21062031","article-title":"Difference in profiles of the gut-derived tryptophan metabolite indole acetic acid between transplanted and non-transplanted patients with chronic kidney disease","volume":"21","author":"Liabeuf","year":"2020","journal-title":"Int J Mol Sci"},{"key":"R33-20250701","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1016\/j.kint.2017.03.053","article-title":"The role of trimethylamine N-oxide as a mediator of cardiovascular complications in chronic kidney disease","volume":"92","author":"Tomlinson","year":"2017","journal-title":"Kidney Int"},{"key":"R34-20250701","doi-asserted-by":"crossref","first-page":"1940","DOI":"10.3390\/ijms24031940","article-title":"Gut microbiota-derived TMAO:A causal factor promoting atherosclerotic cardiovascular disease?","volume":"24","author":"Canyelles","year":"2023","journal-title":"Int J Mol Sci"},{"key":"R35-20250701","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1111\/jcmm.13307","article-title":"Circulating trimethylamine N-oxide and the risk of cardiovascular diseases:A systematic review and meta-analysis of 11 prospective cohort studies","volume":"22","author":"Qi","year":"2018","journal-title":"J Cell Mol Med"},{"key":"R36-20250701","doi-asserted-by":"crossref","first-page":"1842","DOI":"10.1093\/ajcn\/nqac278","article-title":"The association between TMAO, CMPF, and clinical outcomes in advanced chronic kidney disease:Results from the European QUALity (EQUAL) study","volume":"116","author":"Dai","year":"2022","journal-title":"Am J Clin Nutr"},{"key":"R37-20250701","doi-asserted-by":"crossref","first-page":"261","DOI":"10.2215\/CJN.06190518","article-title":"Trimethylamine N-oxide and cardiovascular outcomes in patients with ESKD receiving maintenance hemodialysis","volume":"14","author":"Stubbs","year":"2019","journal-title":"Clin J Am Soc Nephrol"},{"key":"R38-20250701","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1177\/08968608211051809","article-title":"Trimethylamine-N-oxide (TMAO) and clinical outcomes in patients with end-stage kidney disease receiving peritoneal dialysis","volume":"42","author":"Chang","year":"2022","journal-title":"Perit Dial Int"},{"key":"R39-20250701","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/s11684-024-1055-9","article-title":"Gut microbiota-dependent phenylacetylglutamine in cardiovascular disease:Current knowledge and new insights","volume":"18","author":"Song","year":"2024","journal-title":"Front Med"},{"key":"R40-20250701","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1016\/j.cell.2020.02.016","article-title":"Acardiovascular disease-linked gut microbial metabolite acts via adrenergic receptors","volume":"180","author":"Nemet","year":"2020","journal-title":"Cell"},{"key":"R41-20250701","doi-asserted-by":"crossref","first-page":"e0126048","DOI":"10.1371\/journal.pone.0126048","article-title":"Free levels of selected organic solutes and cardiovascular morbidity and mortality in hemodialysis patients:Results from the retained organic solutes and clinical outcomes (ROSCO) investigators","volume":"10","author":"Shafi","year":"2015","journal-title":"PLoS One"},{"key":"R42-20250701","doi-asserted-by":"crossref","first-page":"3479","DOI":"10.1681\/ASN.2015121302","article-title":"Microbiota-derived phenylacetylglutamine associates with overall mortality and cardiovascular disease in patients with CKD","volume":"27","author":"Poesen","year":"2016","journal-title":"J Am Soc Nephrol"},{"key":"R43-20250701","doi-asserted-by":"crossref","first-page":"647","DOI":"10.3390\/toxins11110647","article-title":"FGF23 and phosphate-cardiovascular toxins in CKD","volume":"11","author":"Vogt","year":"2019","journal-title":"Toxins (Basel)"},{"key":"R44-20250701","doi-asserted-by":"crossref","first-page":"55","DOI":"10.2174\/1570161118666200420102100","article-title":"New insights into the role of FGF-23 and klotho in cardiovascular disease in chronic kidney disease patients","volume":"19","author":"Memmos","year":"2021","journal-title":"Curr Vasc Pharmacol"},{"key":"R45-20250701","doi-asserted-by":"crossref","first-page":"835","DOI":"10.5551\/jat.RV22006","article-title":"Role of Chronic Kidney Disease (CKD)-mineral and bone disorder (MBD) in the pathogenesis of cardiovascular disease in CKD","volume":"30","author":"Yamada","year":"2023","journal-title":"J Atheroscler Thromb"},{"key":"R46-20250701","doi-asserted-by":"crossref","first-page":"274","DOI":"10.3390\/toxins13040274","article-title":"Contribution of gut microbiota-derived uremic toxins to the cardiovascular system mineralization","volume":"13","author":"Filipska","year":"2021","journal-title":"Toxins (Basel)"},{"key":"R47-20250701","doi-asserted-by":"crossref","first-page":"6196","DOI":"10.3390\/ijms22126196","article-title":"Uremic toxins and their relation with oxidative stress induced in patients with CKD","volume":"22","author":"Pieniazek","year":"2021","journal-title":"Int J Mol Sci"},{"key":"R48-20250701","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1053\/j.ajkd.2018.04.005","article-title":"Arterial stiffness in CKD:A review","volume":"73","author":"Townsend","year":"2019","journal-title":"Am J Kidney Dis"},{"key":"R49-20250701","doi-asserted-by":"crossref","first-page":"9189362","DOI":"10.1155\/2019\/9189362","article-title":"Chronic kidney disease and pulse wave velocity:A narrative review","volume":"2019","author":"Lioufas","year":"2019","journal-title":"Int J Hypertens"},{"key":"R50-20250701","doi-asserted-by":"crossref","first-page":"115","DOI":"10.4103\/tcmj.tcmj_44_20","article-title":"Arterial stiffness:A brief review","volume":"33","author":"Tsai","year":"2021","journal-title":"Tzu Chi Med J"},{"key":"R51-20250701","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/j.atherosclerosis.2015.05.007","article-title":"The role of vascular biomarkers for primary and secondary prevention. A position paper from the European Society of Cardiology Working Group on peripheral circulation:Endorsed by the Association for Research into Arterial Structure and Physiology (ARTERY) society","volume":"241","author":"Vlachopoulos","year":"2015","journal-title":"Atherosclerosis"},{"key":"R52-20250701","doi-asserted-by":"crossref","first-page":"621","DOI":"10.5551\/jat.RV17041","article-title":"State of the art review:Brachial-Ankle PWV","volume":"27","author":"Tomiyama","year":"2020","journal-title":"J Atheroscler Thromb"},{"key":"R53-20250701","doi-asserted-by":"crossref","first-page":"3310","DOI":"10.1038\/s41440-024-01885-3","article-title":"Current topic of vascular function in hypertension in 2023-2024","volume":"47","author":"Maruhashi","year":"2024","journal-title":"Hypertens Res"},{"key":"R54-20250701","doi-asserted-by":"crossref","first-page":"732","DOI":"10.5551\/jat.RV17043","article-title":"New horizons of arterial stiffness developed using cardio-ankle vascular index (CAVI)","volume":"27","author":"Saiki","year":"2020","journal-title":"J Atheroscler Thromb"},{"key":"R55-20250701","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/j.jjcc.2021.07.011","article-title":"Arterial stiffness in health and disease:The role of cardio-ankle vascular index","volume":"78","author":"Miyoshi","year":"2021","journal-title":"J Cardiol"},{"key":"R56-20250701","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.arcmed.2014.04.002","article-title":"Protein-bound uremic toxins, inflammation, and oxidative stress:A cross-sectional study in stage 3-4 chronic kidney disease","volume":"45","author":"Rossi","year":"2014","journal-title":"Arch Med Res"},{"key":"R57-20250701","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1080\/0886022X.2021.1921797","article-title":"Association between serum indoxyl sulfate levels with carotid-femoral pulse wave velocity in patients with chronic kidney disease","volume":"43","author":"Wang","year":"2021","journal-title":"Ren Fail"},{"key":"R58-20250701","doi-asserted-by":"crossref","first-page":"287","DOI":"10.3390\/toxins14040287","article-title":"Serum P-cresyl sulfate level is an independent marker of peripheral arterial stiffness as assessed using brachial-ankle pulse wave velocity in patients with non-dialysis chronic kidney disease stage 3 to 5","volume":"14","author":"Chang","year":"2022","journal-title":"Toxins (Basel)"},{"key":"R59-20250701","doi-asserted-by":"crossref","first-page":"10","DOI":"10.3390\/toxins12010010","article-title":"Serum P-cresyl sulfate is a predictor of central arterial stiffness in patients on maintenance hemodialysis","volume":"12","author":"Lai","year":"2019","journal-title":"Toxins (Basel)"},{"key":"R60-20250701","doi-asserted-by":"crossref","first-page":"526","DOI":"10.3390\/toxins14080526","article-title":"Serum trimethylamine N-oxide level is associated with peripheral arterial stiffness in advanced non-dialysis chronic kidney disease patients","volume":"14","author":"Hsu","year":"2022","journal-title":"Toxins (Basel)"},{"key":"R61-20250701","doi-asserted-by":"crossref","first-page":"572","DOI":"10.3390\/toxins15090572","article-title":"Serum trimethylamine N-oxide level is positively associated with aortic stiffness measured by carotid-femoral pulse wave velocity in patients undergoing maintenance hemodialysis","volume":"15","author":"Huang","year":"2023","journal-title":"Toxins (Basel)"},{"key":"R62-20250701","doi-asserted-by":"crossref","first-page":"523","DOI":"10.3390\/toxins16120523","article-title":"The association between serum trimethylamine N-oxide and arterial stiffness in chronic peritoneal dialysis patients:A cross-sectional study","volume":"16","author":"Huang","year":"2024","journal-title":"Toxins (Basel)"},{"key":"R63-20250701","doi-asserted-by":"crossref","first-page":"111","DOI":"10.3390\/toxins16020111","article-title":"Serum phenylacetylglutamine among potential risk factors for arterial stiffness measuring by carotid-femoral pulse wave velocity in patients with kidney transplantation","volume":"16","author":"Yang","year":"2024","journal-title":"Toxins (Basel)"},{"key":"R64-20250701","doi-asserted-by":"crossref","first-page":"412","DOI":"10.3390\/toxins12060412","article-title":"How do uremic toxins affect the endothelium?","volume":"12","author":"Cunha","year":"2020","journal-title":"Toxins (Basel)"},{"key":"R65-20250701","doi-asserted-by":"crossref","first-page":"531","DOI":"10.3390\/ijms23010531","article-title":"Impact of uremic toxins on endothelial dysfunction in chronic kidney disease:A systematic review","volume":"23","author":"Harlacher","year":"2022","journal-title":"Int J Mol Sci"},{"key":"R66-20250701","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1016\/j.numecd.2014.04.006","article-title":"Uraemic toxins and cardiovascular disease across the chronic kidney disease spectrum:An observational study","volume":"24","author":"Rossi","year":"2014","journal-title":"Nutr Metab Cardiovasc Dis"},{"key":"R67-20250701","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/s12882-017-0457-1","article-title":"Indoxyl sulfate \u2013The uremic toxin linking hemostatic system disturbances with the prevalence of cardiovascular disease in patients with chronic kidney disease","volume":"18","author":"Kami\u0144ski","year":"2017","journal-title":"BMC Nephrol"},{"key":"R68-20250701","doi-asserted-by":"crossref","first-page":"589","DOI":"10.3390\/toxins11100589","article-title":"Association between serum indoxyl sulfate levels and endothelial function in non-dialysis chronic kidney disease","volume":"11","author":"Wang","year":"2019","journal-title":"Toxins (Basel)"},{"key":"R69-20250701","doi-asserted-by":"crossref","first-page":"3640","DOI":"10.3390\/ijms24043640","article-title":"Indoxyl sulphate retention is associated with microvascular endothelial dysfunction after kidney transplantation","volume":"24","author":"Hobson","year":"2023","journal-title":"Int J Mol Sci"},{"key":"R70-20250701","first-page":"100291","article-title":"Peripheral arterial disease:A small and large vessel problem","volume":"28","author":"Bethel","year":"2023","journal-title":"Am Heart J Plus"},{"key":"R71-20250701","doi-asserted-by":"crossref","first-page":"808","DOI":"10.3390\/toxins12120808","article-title":"Targeting uremic toxins to prevent peripheral vascular complications in chronic kidney disease","volume":"12","author":"Wu","year":"2020","journal-title":"Toxins (Basel)"},{"key":"R72-20250701","doi-asserted-by":"crossref","first-page":"4750","DOI":"10.3390\/jcm11164750","article-title":"The impact of chronic kidney disease on mid-term outcomes after revascularisation of peripheral arterial occlusive disease:Results from a prospective cohort study","volume":"11","author":"Kotov","year":"2022","journal-title":"J Clin Med"},{"key":"R73-20250701","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.atherosclerosis.2012.07.012","article-title":"The role of protein-bound uremic toxins on peripheral artery disease and vascular access failure in patients on hemodialysis","volume":"225","author":"Lin","year":"2012","journal-title":"Atherosclerosis"},{"key":"R74-20250701","doi-asserted-by":"crossref","first-page":"25","DOI":"10.3390\/toxins9010025","article-title":"Impact of indoxyl sulfate on progenitor cell-related neovascularization of peripheral arterial disease and post-angioplasty thrombosis of dialysis vascular access","volume":"9","author":"Wu","year":"2017","journal-title":"Toxins (Basel)"},{"key":"R75-20250701","doi-asserted-by":"crossref","first-page":"696","DOI":"10.3390\/toxins12110696","article-title":"Indoxyl sulfate and incident peripheral artery disease in hemodialysis patients","volume":"12","author":"Lin","year":"2020","journal-title":"Toxins (Basel)"},{"key":"R76-20250701","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1177\/17085381211039941","article-title":"Positive correlation of serum indoxyl sulfate level with peripheral arterial disease in hemodialysis patients","volume":"30","author":"Chiu","year":"2022","journal-title":"Vascular"},{"key":"R77-20250701","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1053\/j.jrn.2021.08.005","article-title":"Biotic supplements in patients with chronic kidney disease:Meta-analysis of randomized controlled trials","volume":"32","author":"Liu","year":"2022","journal-title":"J Ren Nutr"},{"key":"R78-20250701","doi-asserted-by":"crossref","first-page":"850425","DOI":"10.3389\/fnut.2022.850425","article-title":"Probiotics, prebiotics, and synbiotics improve uremic, inflammatory, and gastrointestinal symptoms in end-stage renal disease with dialysis:A network meta-analysis of randomized controlled trials","volume":"9","author":"Yu","year":"2022","journal-title":"Front Nutr"},{"key":"R79-20250701","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1093\/advances\/nmab149","article-title":"Effects of microbiota-driven therapy on circulating indoxyl sulfate and p-cresyl sulfate in patients with chronic kidney disease:A systematic review and meta-analysis of randomized controlled trials","volume":"13","author":"Chen","year":"2022","journal-title":"Adv Nutr"},{"key":"R80-20250701","doi-asserted-by":"crossref","first-page":"4456","DOI":"10.3390\/jcm10194456","article-title":"Effects of probiotics, prebiotics, and synbiotics on uremic toxins, inflammation, and oxidative stress in hemodialysis patients:A systematic review and meta-analysis of randomized controlled trials","volume":"10","author":"Nguyen","year":"2021","journal-title":"J Clin Med"},{"key":"R81-20250701","doi-asserted-by":"crossref","first-page":"2416609","DOI":"10.1080\/0886022X.2024.2416609","article-title":"Effects of resistant starch supplementation on renal function and inflammatory markers in patients with chronic kidney disease:A meta-analysis of randomized controlled trials","volume":"46","author":"Zhang","year":"2024","journal-title":"Ren Fail"},{"key":"R82-20250701","doi-asserted-by":"crossref","first-page":"688","DOI":"10.3390\/toxins13100688","article-title":"Protein-bound uremic toxins lowering effect of sevelamer in pre-dialysis chronic kidney disease patients with hyperphosphatemia:A randomized controlled trial","volume":"13","author":"Takkavatakarn","year":"2021","journal-title":"Toxins (Basel)"},{"key":"R83-20250701","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1093\/ndt\/gfaa335","article-title":"Effect of fructooligosaccharide on endothelial function in CKD patients:A randomized controlled trial","volume":"37","author":"Armani","year":"2021","journal-title":"Nephrol Dial Transplant"},{"key":"R84-20250701","article-title":"Effects of high amylose-resistant starch on gut microbiota and uremic toxin levels in patients with stage-G3a-G4 chronic kidney disease:A randomized trial","author":"Headley","year":"2024","journal-title":"J Ren Nutr"},{"key":"R85-20250701","doi-asserted-by":"crossref","first-page":"30","DOI":"10.2215\/CJN.05340610","article-title":"Indoxyl sulfate-induced endothelial dysfunction in patients with chronic kidney disease via an induction of oxidative stress","volume":"6","author":"Yu","year":"2011","journal-title":"Clin J Am Soc Nephrol"},{"key":"R86-20250701","doi-asserted-by":"crossref","first-page":"942","DOI":"10.3349\/ymj.2016.57.4.942","article-title":"AST-120 improves microvascular endothelial dysfunction in end-stage renal disease patients receiving hemodialysis","volume":"57","author":"Ryu","year":"2016","journal-title":"Yonsei Med J"},{"key":"R87-20250701","doi-asserted-by":"crossref","first-page":"676345","DOI":"10.3389\/fphar.2021.676345","article-title":"Efficacy of AST-120 for patients with chronic kidney disease:A network meta-analysis of randomized controlled trials","volume":"12","author":"Su","year":"2021","journal-title":"Front Pharmacol"},{"key":"R88-20250701","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.3390\/biomedicines11051312","article-title":"Effect of low protein diet supplemented with ketoanalogs on endothelial function and protein-bound uremic toxins in patients with chronic kidney disease","volume":"11","author":"Chang","year":"2023","journal-title":"Biomedicines"},{"key":"R89-20250701","doi-asserted-by":"crossref","first-page":"622","DOI":"10.3390\/toxins13090622","article-title":"Removal of protein-bound uremic toxins using binding competitors in hemodialysis:A narrative review","volume":"13","author":"Maheshwari","year":"2021","journal-title":"Toxins (Basel)"}],"container-title":["Tzu Chi Medical Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/tcmj.tcmj_293_24","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T15:37:04Z","timestamp":1787067424000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/tcmj.tcmj_293_24"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,11]]},"references-count":89,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.4103\/tcmj.tcmj_293_24","relation":{},"ISSN":["1016-3190","2223-8956"],"issn-type":[{"value":"1016-3190","type":"print"},{"value":"2223-8956","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,11]]},"assertion":[{"value":"2024-11-08","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-01-15","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}